Weight Loss News and Research

Latest Weight Loss News and Research

New REACT medical trial for early diagnosis of lung cancer

Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.

2 Nov 2010

More companies push employee wellness programs

General Mills has a corporate culture that consistently encourages workers to stay active and healthy. It's part of the consumer-products company's long-established wellness program, which General Mills says has helped it keep increases in health-care costs in the single digits, way below the national average

2 Nov 2010

FDA new approvals, antibiotic and neurological drugs

Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.

31 Oct 2010

Study evaluates community weight loss campaign through online competition

In a time when deficits have reduced states' budgets and the services they can provide, a new study shows that the Internet might offer communities a low-cost way to motivate their overweight residents to lose pounds.

30 Oct 2010

Bed rest may harm mother and baby in pregnancy complications

Bed rest may not be the best option for preventing preterm labor and may even cause harm to the mother and baby, according to an integrative literature review in a special issue on "Women's Health Across the Lifespan" in Biological Research for Nursing (published by SAGE).

30 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

VIVUS receives FDA CRL for QNEXA NDA

VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

29 Oct 2010

Systemic amyloidosis patient to receive triple organ transplant

In 2005, then 40-year-old Walt McGuire was playing hockey twice a week, working full-time and chasing his young daughter. Then one day, he noticed after one trip up the stairs to catch her, he couldn't catch his breath. A few days later his legs were swollen. After numerous trips to different doctors, McGuire finally was diagnosed with a rare blood disorder called amyloidosis.

28 Oct 2010

Lifestyle intervention programs result in significant weight loss for overweight and severly obese adults

Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online October 9 by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles appear in the October 27 print issue of JAMA.

27 Oct 2010

DGAC Report highlights effective approaches to facilitate better eating habits among Americans

In an insightful Commentary in the November issue of the Journal of the American Dietetic Association, Linda Van Horn, PhD, RD, Editor-in-Chief of the Journal, Chair of the Dietary Guidelines Advisory Committee, and Professor and Associate Dean, Northwestern University, Feinberg School of Medicine, highlights the key features and noteworthy findings of the 2010 US Dietary Guidelines Advisory Committee (DGAC) Report.

26 Oct 2010

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.

26 Oct 2010

Daily dose of whole body vibration reduces bone density loss

A daily dose of whole body vibration may help reduce the usual bone density loss that occurs with age, Medical College of Georgia researchers report.

25 Oct 2010

Arena's NDA receives Complete Response Letter for lorcaserin

Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese

25 Oct 2010

New guidelines feature various key updates for stroke or TIA survivors

Treating metabolic syndrome and undergoing carotid angioplasty may prevent recurrent stroke or transient ischemic attack, according to revised American Heart Association/American Stroke Association guidelines.

22 Oct 2010

Parent-only treatments for childhood obesity work effectively: Researchers

A study led by a researcher at the University of California, San Diego School of Medicine indicates that parent-only treatments for childhood obesity work equally as well as plans that include parents and child, while at the same time more cost effective and potentially easier for families. The results were published today in the advanced online edition of the journal Obesity.

22 Oct 2010

FDA issues complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON™ (exenatide extended-release for injectable suspension).

21 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

New online community to discuss weight loss management

Frank Cruz has been at the forefront of a campaign to stop the spread of obesity in America. In an effort to give people a chance to share their stories and struggles with weight, Frank began blogging on the website "Fat Man Unleashed," an online community of voices who have all battled with what Frank calls, "The Yo-yo Life."

20 Oct 2010

ASBP reviews current rules of prescription medication to treat obesity in Kansas

In response to the alarming increase in the overweight and obese population in Kansas, a representative of the American Society of Bariatric Physicians (ASBP) recently testified to the Kansas State Board of Healing Arts. ASBP is America's oldest and most experienced society devoted to the medical treatment of overweight and obesity and associated health conditions and risks.

20 Oct 2010

Arcadia Biosciences receives Canadian marketing clearance for SONOVA 400 health product

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, today announced that Health Canada has granted the company clearance to sell SONOVA 400 in Canada. With the December 2009 completion of the New Dietary Ingredient (NDI) regulatory process in the United States, Arcadia is now able to make the health-maintaining oil available throughout the US and Canada.

19 Oct 2010